AIR-STABLE N-CHANNEL ORGANIC ELECTRONIC DEVICES
    1.
    发明申请
    AIR-STABLE N-CHANNEL ORGANIC ELECTRONIC DEVICES 有权
    空气稳定的N沟道有机电子器件

    公开(公告)号:US20110248267A1

    公开(公告)日:2011-10-13

    申请号:US13079879

    申请日:2011-04-05

    IPC分类号: H01L21/22 H01L29/04

    摘要: In connection with various example embodiments, an organic electronic device is provided with an organic material that is susceptible to decreased mobility due to the trapping of electron charge carriers in response to exposure to air. The organic material is doped with an n-type dopant that, when combined with the organic material, effects air stability for the doped organic material (e.g., exhibits a mobility that facilitates stable operation in air, such as may be similar to operation in inert environments). Other embodiments are directed to organic electronic devices n-doped and exhibiting such air stability.

    摘要翻译: 结合各种示例实施例,有机电子器件被提供有有机材料,其由于电子电荷载体响应于暴露于空气而被俘获而易于降低迁移率。 有机材料掺杂有n型掺杂剂,当与有机材料组合时,掺杂的有机材料具有空气稳定性(例如,表现出促进在空气中稳定运行的迁移率,例如可以类似于在惰性中的操作) 环境)。 其他实施方案涉及n掺杂并表现出这种空气稳定性的有机电子器件。

    n-Type doped organic materials and methods therefor
    2.
    发明授权
    n-Type doped organic materials and methods therefor 有权
    n型掺杂有机材料及其方法

    公开(公告)号:US09133130B2

    公开(公告)日:2015-09-15

    申请号:US13080564

    申请日:2011-04-05

    申请人: Peng Wei Zhenan Bao

    发明人: Peng Wei Zhenan Bao

    摘要: In accordance with various embodiments, an organic electronic device includes an n-type dopant material including an imidazole-based material having a hydrogen-based material bonded between nitrogen atoms. The n-type dopant material n-dopes an organic material, and can be used to mitigate degradation in mobility due to conditions such as exposure to ambient atmosphere, which can effect an undesirable reduction in charge transport. Other embodiments are directed to carbon nanotubes or graphene structures with this type of n-type dopant, wherein the Fermi level for the carbon nanotubes or graphene structures is below −2.5 eV to effect such n-type doping.

    摘要翻译: 根据各种实施方案,有机电子器件包括n型掺杂剂材料,其包括在氮原子之间键合有氢基材料的咪唑类材料。 n型掺杂剂材料掺杂有机材料,并且可以用于减轻由于诸如暴露于环境大气的条件而导致的迁移率的降低,这可能导致电荷传输的不期望的减少。 其他实施方案涉及具有这种类型的n型掺杂剂的碳纳米管或石墨烯结构,其中碳纳米管或石墨烯结构的费米能级低于-2.5eV以实现这种n型掺杂。

    Air-stable n-channel organic electronic devices
    3.
    发明授权
    Air-stable n-channel organic electronic devices 有权
    空气稳定的n沟道有机电子器件

    公开(公告)号:US09040400B2

    公开(公告)日:2015-05-26

    申请号:US13079879

    申请日:2011-04-05

    摘要: In connection with various example embodiments, an organic electronic device is provided with an organic material that is susceptible to decreased mobility due to the trapping of electron charge carriers in response to exposure to air. The organic material is doped with an n-type dopant that, when combined with the organic material, effects air stability for the doped organic material (e.g., exhibits a mobility that facilitates stable operation in air, such as may be similar to operation in inert environments). Other embodiments are directed to organic electronic devices n-doped and exhibiting such air stability.

    摘要翻译: 结合各种示例实施例,有机电子器件被提供有有机材料,其由于电子电荷载体响应于暴露于空气而被俘获而易于降低迁移率。 有机材料掺杂有n型掺杂剂,当与有机材料组合时,掺杂的有机材料具有空气稳定性(例如,表现出促进在空气中稳定运行的迁移率,例如可以类似于在惰性中的操作) 环境)。 其他实施方案涉及n掺杂并表现出这种空气稳定性的有机电子器件。

    Fusion Protein Comprising Circularly Permuted Form Of Trail/Apo2L, Coding Gene And Use Thereof
    9.
    发明申请
    Fusion Protein Comprising Circularly Permuted Form Of Trail/Apo2L, Coding Gene And Use Thereof 有权
    融合蛋白包含循环形式的Trail / Apo2L,编码基因及其用途

    公开(公告)号:US20140342994A1

    公开(公告)日:2014-11-20

    申请号:US14344289

    申请日:2011-09-16

    IPC分类号: A61K38/17 A61K45/06 C07K14/47

    摘要: Provided is a fusion protein comprising circularly permuted form of TRAIL, and the fusion protein contains circularly permuted form of TRAIL and oligopeptides located at the N-terminus and/or C-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines. The components of the circularly permuted form of TRAIL from N-terminus to C-terminus are: (a) amino acids 135-281 of TRAIL, (b) a linker, and (c) amino acids 121-135 of TRAIL or amino acids 114-135 of TRAIL or amino acids 95-135 of TRAIL or any fragments of amino acids 95-135 of TRAIL containing amino acids 121-135 of TRAIL. Also provided is a method for treating cancer by using the fusion protein.

    摘要翻译: 提供了包含循环形式的TRAIL的融合蛋白,并且融合蛋白包含位于置换形式的N末端和/或C末端的循环形式的TRAIL和寡肽。 寡肽含有由3-10组氨酸组成的重复序列。 从N末端到C末端的循环形式的TRAIL的组分是:(a)TRAIL的氨基酸135-281,(b)接头,和(c)TRAIL或氨基酸的氨基酸121-135 TRAIL的114-135或TRAIL的氨基酸95-135或含有TRAIL的第121-135位氨基酸的TRAIL的任何氨基酸95-135的片段。 还提供了通过使用融合蛋白治疗癌症的方法。

    Use Of Detection Of Aspartate Transaminase And Lactate Dehydrogenase In Early Evaluation Of Clinical Efficacy Of Antitumor Intervention Measure
    10.
    发明申请
    Use Of Detection Of Aspartate Transaminase And Lactate Dehydrogenase In Early Evaluation Of Clinical Efficacy Of Antitumor Intervention Measure 审中-公开
    使用天冬氨酸转氨酶和乳酸脱氢酶在早期评估抗肿瘤干预措施的临床疗效

    公开(公告)号:US20140206025A1

    公开(公告)日:2014-07-24

    申请号:US14240311

    申请日:2011-08-30

    IPC分类号: G01N33/50

    摘要: The present invention relates to a method for early evaluation of clinical efficacy of antitumor intervention measure, comprising evaluating the efficacy of the antitumor intervention measure by assaying whether the content of a tumor-damaging biomarker(s) in the blood of a patient having tumor rises as compared to the baseline level before treatment within a time window after the patients receives at least one antitumor intervention measure. In preferable embodiments, the tumor-damaging biomarker(s) is selected from a group consisting of Alanine Aminotransferase (ALT), Aspartate Transaminase (AST), Lactate Dehydrogenase (LDH); said tumor is multiple myeloma; said antitumor intervention measure is the administration of CPT alone or the administration of CPT in combination with thalidomide.

    摘要翻译: 本发明涉及一种用于早期评估抗肿瘤干预措施的临床疗效的方法,包括通过测定患有肿瘤的患者的血液中的肿瘤损伤性生物标志物的含量是否上升来评估抗肿瘤干预措施的功效 与患者接受至少一种抗肿瘤干预措施后的时间窗内治疗前的基线水平相比。 在优选的实施方案中,肿瘤破坏性生物标志物选自丙氨酸氨基转移酶(ALT),天冬氨酸转氨酶(AST),乳酸脱氢酶(LDH); 所述肿瘤是多发性骨髓瘤; 所述抗肿瘤干预措施是单独使用CPT或与沙利度胺组合使用CPT。